AEON – aeon biopharma, inc. class a (US:NASDAQ)

News

AEON Biopharma, Inc. (NASDAQ: AEON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
AEON Biopharma, Inc. (NASDAQ: AEON) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com